Industry News
Glythera Licenses Novel Payload Class from Cancer Research UK for the Development of Next-Generation Antibody Drug Conjugates
Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor programme for the development of antibody drug conjugates
